Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
Département de Biochimie et Médecine Moléculaire, Université de Montréal, Succursale Centre-Ville, Montréal, QC, Canada; Maisonneuve-Rosemont Hospital Research Centre, Montréal, QC, Canada.
Arch Med Res. 2021 Apr;52(3):243-251. doi: 10.1016/j.arcmed.2020.10.021. Epub 2020 Nov 12.
Drug repurposing has increased in recent years as an attractive option for treating a number of diseases. Compared to those brought forward via traditional chemical development, drugs intended for repurposing can enter the market faster and with lower investment from pharmaceutical companies. However, a common trend is to focus on diseases that yield higher returns to the industry, such as cancer and common metabolic and inflammatory conditions, resulting in orphan illnesses and neglected tropical diseases having fewer repurposing options for affected patients. In addition, certain legal concerns, including limited patent coverage for the repurposed drugs and pharmacological challenges in performing clinical trials, reduce the likelihood of success. In this review, we discuss the most important concerns that affect the pathway of drug repurposing, with special emphasis on the economic revenues, government-industry associations, and legal considerations that together impact the pharmaceutical industry's decision-making on which compounds may be eligible for repurposing.
近年来，药物重定位作为治疗多种疾病的一种有吸引力的选择而日益增多。与通过传统化学开发提出的药物相比，用于重定位的药物可以更快地进入市场，并且制药公司的投资也更低。然而，一个常见的趋势是专注于那些能够给行业带来更高回报的疾病，如癌症和常见的代谢和炎症性疾病，这导致孤儿病和被忽视的热带病对受影响患者的重定位选择较少。此外，某些法律方面的担忧，包括对重定位药物的专利保护有限以及在进行临床试验方面的药理学挑战，降低了成功的可能性。在这篇综述中，我们讨论了影响药物重定位途径的最重要的关注点，特别强调了经济收益、政府与行业协会以及法律方面的考虑因素，这些因素共同影响着制药行业对哪些化合物可能有资格进行重定位的决策。
